← Eichor
Condition: Relapsed And Refractory Multiple Myeloma Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Relapsed And Refractory Multiple Myeloma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Study of IMV102 in Patients With Relapsed/Refractory Multiple Myeloma
EARLY_Phase 1 · 4 location(s) · Suzhou Immunofoco Biotechnology Co., Ltd · NCT07493135In VIVO CAR-T Therapy for Relapsed/Refractory Hematological Malignancies
Phase 1 · 1 location(s) · Chongqing Precision Biotech Co., Ltd · NCT07239323A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilz
Phase 1/Phase 2 · 84 location(s) · BeOne Medicines · NCT04973605A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in
Phase 1 · 2 location(s) · Mayo Clinic · NCT03017820Infliximab for Cytokine Release Syndrome Prophylaxis During Teclistamab or Talquetamab Therapy in Patients With Relapsed
Phase 2 · 1 location(s) · Naresh Bumma · NCT07657312BCMA-CD19 cCAR in Multiple Myeloma and Plasmacytoid Lymphoma
Phase 1 · 2 location(s) · iCell Gene Therapeutics · NCT04162353Nanobody-based Biepitope CAR-T Cells Targeting BCMA in the Treatment of R/RMM
Phase 1/Phase 2 · 1 location(s) · Union Hospital, Tongji Medical College, Huazhong University · NCT06503107Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma
Phase 2 · 3 location(s) · University of Miami · NCT05530421Response-Based Dose Reduction of Linvoseltamab in the Treatment of Relapsed, Refractory, or Triple-Class Relapsed/Refrac
Phase 1/Phase 2 · 1 location(s) · Fred Hutchinson Cancer Center · NCT07181941A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Hav
Phase 3 · 90 location(s) · Pfizer · NCT05020236Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With Relapsed or Refractory Multiple
Phase 1/Phase 2 · 42 location(s) · Alliance for Clinical Trials in Oncology · NCT06232044Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma
Phase 1 · 12 location(s) · Opna Bio LLC · NCT06433947A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma
Phase 1 · 10 location(s) · Kelonia Therapeutics, Inc. · NCT07075185A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma
Phase 2 · 2 location(s) · Oncotherapeutics · NCT06115135Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
Phase 2 · 20 location(s) · CellCentric Ltd. · NCT07096778A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in R
Phase 3 · 12 location(s) · Hangzhou Sumgen Biotech Co., Ltd. · NCT06508983A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light
Phase 1 · 29 location(s) · Janssen Research & Development, LLC · NCT05652335A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administrati
Phase 2 · 1 location(s) · Janssen Research & Development, LLC · NCT07589634A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia
Phase 1 · 1 location(s) · Nanjing IASO Biotechnology Co., Ltd. · NCT05759793PRO and Wearable Data Insights From Individuals With R/R Multiple Myeloma
NA · 1 location(s) · Pack Health · NCT05956457Safety and Efficacy of Anti-BCMA/FcRL5 CAR-T Cell Therapy in Treating Relapsed and Refractory Multiple Myeloma (R/R MM)
Phase 1/Phase 2 · 1 location(s) · Xuzhou Medical University · NCT06759181A Novel CAR-T Combined Expression of IL-15 in the Treatment of Malignant Hematological Tumors
NA · 1 location(s) · Shanxi Bethune Hospital · NCT06783816HCMT/MM2401: Ph2 Study of Selinexor + Bispecific Antibody for RRMM
Phase 2 · 1 location(s) · Duke University · NCT06822972Radioimmunotherapy (111Indium/225Actinium-DOTA-daratumumab) for the Treatment of Relapsed/Refractory Multiple Myeloma
Phase 1 · 1 location(s) · City of Hope Medical Center · NCT05363111An Open-label, Single-arm Clinical Study to Evaluate the Safety and Preliminary Efficacy of OriV508 Injection in Treatin
EARLY_Phase 1 · 1 location(s) · Union Hospital, Tongji Medical College, Huazhong University · NCT07101705A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
Phase 2 · 78 location(s) · Janssen Research & Development, LLC · NCT04634552CAR-T in Relapsed/Refractory Multiple Myeloma
Phase 2 · 2 location(s) · Dr. Zaineb Akram · NCT07689058Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma
Phase 1 · 2 location(s) · Mayo Clinic · NCT06508463Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma
Phase 1/Phase 2 · 24 location(s) · Heidelberg Pharma AG · NCT04879043A Study to Investigate the Safety and Efficacy of SAR446523 Injected Subcutaneously in Adult Participants With Relapsed/
Phase 1 · 19 location(s) · Sanofi · NCT06630806
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.